HCW Biologics has requested an FDA meeting for HCW11-018b, its tetravalent T-cell engager for solid tumors, targeting trials in the first half o 2027.
HCW Biologics has requested a Type B
"We are pleased to have reached this important milestone in the development of HCW11-018b and look forward to discussing our proposed clinical trial designs, nonclinical testing programs, and CMC [chemistry, manufacturing, and controls] data with the FDA," said
HCW11-018b is administered by subcutaneous injection and, in preclinical studies, has shown the ability to target tissue factor-expressing cancer cells and activate CD3-positive effector T cells while reducing immunosuppression in the tumor microenvironment, an effect the company says is particularly relevant in gynecologic and pancreatic cancers.1
Tissue factor is overexpressed on a range of solid tumors, including pancreatic and triple-negative breast cancers, at levels reported up to 1000-fold higher than in normal tissue, making it an actively studied target for T-cell-engaging and CAR-based immunotherapies.2 First-generation TCEs, beginning with blinatumomab's 2014 approval, established the modality's clinical potential but have faced recurring challenges in solid tumors, including antigen selection, limited efficacy, tolerability, and complex manufacturing,2 challenges that next-generation TCE programs, including HCW11-018b, are designed to address.3
HCW11-018b, which the company named the Big BiTE (bispecific T-cell engager), combines a tissue factor-targeting BiTE arm with interleukin (IL)-15 immune stimulation and a transforming growth factor beta (TGF-β) trap intended to counter tumor-microenvironment immunosuppression without the Fc fusion architecture common to other multispecific formats.1 In preclinical studies, the company reported that HCW11-018b induced sustained, antigen-specific tumor killing and enhanced CD8⁺ T-cell activation without triggering cytokine release syndrome within its therapeutic dose range, a toxicity that has limited some earlier-generation TCEs.1
The company said FDA and other regulatory agencies have approved 8 TCEs across 12 indications to date, generating multibillion-dollar annual sales despite the limited number of approved uses, a track record the company said has driven continued high-value partnership activity in both oncology and autoimmune disease.1
"We believe we have established a robust, streamlined, and cost-efficient manufacturing process capable of producing high-quality cGMP material to support HCW11-018b in clinical development and potential future commercialization," Dr Wong said in the release.1 "Our manufacturing process is based on high-producing recombinant CHO [Chinese hamster ovary] cell lines and a proprietary monoclonal antibody needed for the affinity purification process."
The update follows an earlier 2026 clinical milestone for HCW Biologics' immunology pipeline. In June, the company reported
HCW11-018b has not yet entered human testing, and requesting an FDA meeting does not guarantee a particular regulatory pathway or timeline for the program. All efficacy and safety findings described for HCW11-018b to date are preclinical, including toxicity data in nonhuman primates, and have not yet been replicated in human trials.1
